New Releases from NCBI BookshelfTralokinumab (Adtralza): CADTH Reimbursement Recommendation: Indication: For the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Tralokinumab can be used with or without topical corticosteroids [Internet].​Tralokinumab (Adtralza): CADTH Reimbursement Recommendation: Indication: For the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Tralokinumab can be used with or without topical corticosteroids [Internet].